WisdomTree launched an exchange-traded fund (ETF) in London and Frankfurt that tracks an index of leading companies engaged in genetics and biotechnology.
The WisdomTree BioRevolution UCITS ETF (LSE:WDNA), which has an expense ratio of 0.45%, tracks the WisdomTree BioRevolution ESG Screened Index.
Dr Jamie Metzl, one of the world’s leading technology futurists, has advised th company.
“The biology revolution is creating a historic investment opportunity equivalent to the industrial and internet revolutions,” said Chris Gannatti, global head of research at WisdomTree.
“Advancements in biotechnology could represent the greatest innovations of our lifetime. The biology revolution has huge potential to address and mitigate some of the most pressing challenges facing humanity today whether that be climate change, food scarcity or controlling diseases and pandemics. New and transformative innovations could have a profound impact on society and the environment, improving the quality of life for many.”
Metzl said: “The genetics and biotechnology revolutions won’t just change our healthcare systems, allowing us to live healthier and longer lives. They will also fundamentally transform our world far beyond healthcare.
“The same technologies driving healthcare innovation will have a seismic impact on industries including agriculture, materials, energy, and information processing, revolutionizing the ways we treat disease, grow food, produce materials, and process data. If the nineteenth was the century of chemistry and the twentieth of physics, the twenty-first will be the century of biology. I am delighted to be collaborating with the amazing team at WisdomTree and uncovering some of the opportunities presented by this historic megatrend.”
The ETF follows other thematic products providing exposure to artificial intelligence, cloud computing, cyber security and battery technology industries.